Causeway International

Causeway International Accelerating access to innovative
through active management of a value driven, cost effective, IP sa

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy - PubMed
19/09/2024

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy - PubMed

Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten was developed to target th...

‘Gamechanging’ drug to prevent hot flushes wins approval in UK | Women's health | The Guardian
06/09/2024

‘Gamechanging’ drug to prevent hot flushes wins approval in UK | Women's health | The Guardian

Veoza, also known as fezolinetant, is prescription-only and will be available privately from January

Novel Mechanisms Set FDA-Approved Amivantamab-Lazertinib Combo Apart in NSCLC
02/09/2024

Novel Mechanisms Set FDA-Approved Amivantamab-Lazertinib Combo Apart in NSCLC

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.

Movantik (naloxegol) for the treatment of opioid-induced constipation
10/07/2024

Movantik (naloxegol) for the treatment of opioid-induced constipation

Movantik (naloxegol) is an opioid antagonist therapy for the treatment of opioid-induced constipation in adult patients with chronic, non-cancerous pain.

Experts say Pakistan budget massively negative for struggling healthcare sector - Pakistan - Business Recorder
07/07/2024

Experts say Pakistan budget massively negative for struggling healthcare sector - Pakistan - Business Recorder

KARACHI: Pharmaceutical industry experts have expressed concerns regarding the recent taxation changes in Pakistan,...

'Impressive' New Data on Novel Schizophrenia Hopeful KarXT
27/06/2024

'Impressive' New Data on Novel Schizophrenia Hopeful KarXT

The novel investigational antipsychotic KarXT was effective and well tolerated in adults with schizophrenia experiencing acute psychosis in a second phase 3 trial.

A Brand New Blood Pressure Drug: Tryvio (Aprocitentan) | The People's Pharmacy
01/04/2024

A Brand New Blood Pressure Drug: Tryvio (Aprocitentan) | The People's Pharmacy

Will a brand new & different blood pressure drug change the treatment of hypertension? Meet Tryvio (aprocitentan). What are the pros & cons?

FDA approves antibiotic combination for hospital-acquired pneumonia | CIDRAP
17/02/2024

FDA approves antibiotic combination for hospital-acquired pneumonia | CIDRAP

The US Food and Drug Administration (FDA) yesterday approved the combination antibiotic sulbactam-durlobactam for the treatment of patients with hospital-related bacterial pneumonia caused by a highly resistant superbug.

FDA Approves First Medication to Treat Severe Frostbite | FDA
15/02/2024

FDA Approves First Medication to Treat Severe Frostbite | FDA

The FDA approved an injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

Exciting new cancer drug kinder than chemotherapy
17/01/2024

Exciting new cancer drug kinder than chemotherapy

Arthur, 11, was one of the first in the UK to try blinatumomab, for his type of blood cancer.

Address

Karachi

Opening Hours

Monday 09:00 - 18:00
Tuesday 09:00 - 18:00
Wednesday 09:00 - 18:00
Thursday 09:00 - 18:00
Friday 09:00 - 18:00
Saturday 09:00 - 18:00

Telephone

00922134549920

Website

Alerts

Be the first to know and let us send you an email when Causeway International posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Causeway International:

Shortcuts

Share

Category